RWRui Qing Wang

Rui Qing Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rui Qing Wang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Chen

    Department of Laboratory Animals, College of Animal Sciences, Jilin University, Changchun, People’s Republic of China

    1 shared publication
  • Jing Yi Zhao

    The Second Clinical Medical College of Jilin University, Changchun, China

    1 shared publication
  • Jinping Hu

    Department of Laboratory Animals, College of Animal Sciences, Jilin University, Changchun, People’s Republic of China

    1 shared publication
  • Mei Liang Wu

    The Eye Center, The Second Hospital of Jilin University, Changchun, China

    1 shared publication
  • Qing Zhang

    Department of Laboratory Animals, College of Animal Sciences, Jilin University, Changchun, People’s Republic of China

    1 shared publication
  • Song He

    Department of Laboratory Animals, College of Animal Sciences, Jilin University, Changchun, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    The application of high-throughput sequencing technology in corneal diseases

    by Jing Yi Zhao, Yu Xi He, Mei Liang Wu, Rui Qing Wang

    High-throughput sequencing technology, also known as next-generation sequencing technology, can explore new biomarkers and specific gene mutations. It has a pivotal role in promoting the gene research, which can limit the detection area, lessen the time needed for sequencing. Also, it can quickly screen out the suspected pathogenic genes of patients, gain the necessary genetic data, and provide the basis for clinical diagnosis and genetic counseling. In the research of corneal diseases, through the DNA sequencing of patients’ diseased cells, it can provide a deeper understanding of corneal diseases and improve the diagnosis, classification and treatment alternatives of various corneal diseases. This article will introduce the application progress of high-throughput sequencing technology in corneal diseases, which will help to understand the application of this technology in various corneal diseases.


  • Open Access

    Investigation of LGALS2 expression in the TCGA database reveals its clinical relevance in breast cancer immunotherapy and drug resistance

    by Song He, Zhonghao Ji, Qing Zhang, Xiwen Zhang, Jian Chen, Jinping Hu, Ruiqing Wang, Yu Ding

    Breast cancer (BRCA) is known as the leading cause of death in women worldwide and has a poor prognosis. Traditional therapeutic strategies such as surgical resection, radiotherapy and chemotherapy can cause adverse reactions such as drug resistance. Immunotherapy, a new treatment approach with fewer side effects and stronger universality, can prolong the survival of BRCA patients and even achieve clinical cure. However, due to population heterogeneity and other reasons, there are still certain factors that limit the efficacy of immunotherapy. Therefore, the importance of finding new tumor immune biomarker cannot be emphasized enough. Studies have reported that LGALS2 was closely related to immunotherapy efficacy, however, it is unclear whether it can act as an immune checkpoint for BRCA immunotherapy. In the current study, changes in LGALS2 expression were analyzed in public datasets such as TCGA-BRCA. We found that LGALS2 expression was associated with immune infiltration, drug resistance and other characteristics of BRCA. Moreover, high LGALS2 expression was closely related to immunotherapy response, and was associated with methylation modifications and clinical resistance for the first time. These findings may help to elucidate the role of LGALS2 in BRCA for the development and clinical application of future immunotherapy strategies against BRCA.